CY1112843T1 - Μεθοδος παρασκευης υβριδικων αντισωματων - Google Patents

Μεθοδος παρασκευης υβριδικων αντισωματων

Info

Publication number
CY1112843T1
CY1112843T1 CY20121100520T CY121100520T CY1112843T1 CY 1112843 T1 CY1112843 T1 CY 1112843T1 CY 20121100520 T CY20121100520 T CY 20121100520T CY 121100520 T CY121100520 T CY 121100520T CY 1112843 T1 CY1112843 T1 CY 1112843T1
Authority
CY
Cyprus
Prior art keywords
hybrid
antibodies
framework regions
antibody fragments
hybrid antibodies
Prior art date
Application number
CY20121100520T
Other languages
Greek (el)
English (en)
Inventor
Russell Rother
Dayang Wu
Original Assignee
Alexion Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals, Inc. filed Critical Alexion Pharmaceuticals, Inc.
Publication of CY1112843T1 publication Critical patent/CY1112843T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CY20121100520T 2001-12-03 2012-06-07 Μεθοδος παρασκευης υβριδικων αντισωματων CY1112843T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33659101P 2001-12-03 2001-12-03
EP02794114A EP1461428B1 (en) 2001-12-03 2002-12-03 Method for producing hybrid antibodies

Publications (1)

Publication Number Publication Date
CY1112843T1 true CY1112843T1 (el) 2016-02-10

Family

ID=23316785

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100520T CY1112843T1 (el) 2001-12-03 2012-06-07 Μεθοδος παρασκευης υβριδικων αντισωματων

Country Status (12)

Country Link
US (1) US7399594B2 (https=)
EP (2) EP2298817A1 (https=)
JP (3) JP4723810B2 (https=)
AT (1) ATE550352T1 (https=)
AU (1) AU2002359568B2 (https=)
CA (1) CA2468744C (https=)
CY (1) CY1112843T1 (https=)
DK (1) DK1461428T3 (https=)
ES (1) ES2384100T3 (https=)
PT (1) PT1461428E (https=)
SI (1) SI1461428T1 (https=)
WO (1) WO2003048321A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7393648B2 (en) * 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
EP1521776A2 (en) * 2002-07-04 2005-04-13 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
MXPA06000258A (es) * 2003-07-15 2006-07-03 Cambridge Antibody Tech Moleculas de anticuerpo humano para interleucina-13.
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
CA2545756A1 (en) * 2003-11-07 2005-05-26 Curagen Corporation Antibodies against secretoryleukocyte protease inhibitor
DE10353175A1 (de) * 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2005058251A2 (en) * 2003-12-15 2005-06-30 Dendreon Corporation Hla-dr-specific antibodies, compositions and methods
CA2562034A1 (en) * 2004-03-31 2005-10-20 Jin Lu Method and apparatus for analyzing and generating human antibody amino acid and nucleic acid sequences
US20060263787A1 (en) * 2004-05-10 2006-11-23 Evans Glen A Immunoglobulin-like variable chain binding polypeptides and methods of use
GB0414886D0 (en) * 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
EP1907001B1 (en) 2005-06-17 2015-07-15 Merck Sharp & Dohme Corp. Ilt3 binding molecules and uses therefor
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
CA2655903A1 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
ME03057B (me) 2007-12-07 2019-01-20 Zymogenetics Inc Molekuli humanizovanih antitela specifični za il-31
KR101759457B1 (ko) * 2007-12-21 2017-07-31 메디뮨 리미티드 인터루킨-4 수용체 알파(ＩＬ-4Ｒα)에 대한 결합 구성원-173
US20110052565A1 (en) * 2007-12-21 2011-03-03 National Research Council Of Canada Non-aggregating human vh domains
WO2009131605A2 (en) * 2008-01-28 2009-10-29 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2356154A4 (en) * 2008-11-06 2012-12-19 Alexion Pharma Inc DEVELOPMENT OF REDUCED IMMUNOGENICITY ANTIBODIES AND METHODS OF MANUFACTURING THEREOF
EP2411050A4 (en) * 2009-03-25 2013-07-17 Vet Therapeutics Inc ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
EP2542258A4 (en) * 2010-03-04 2013-08-21 Vet Therapeutics Inc ON CD52 MONOCLONAL ANTIBODIES
EP3323830B1 (en) * 2010-06-19 2023-08-23 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
CN102251013A (zh) * 2011-02-22 2011-11-23 北京市肿瘤防治研究所 一个识别肿瘤起始细胞的抗体和抗原及其应用
HRP20182129T1 (hr) * 2012-10-12 2019-02-08 Adc Therapeutics Sa Konjugati protutijelo - pirolobenzodiazepin
EP2906296B1 (en) 2012-10-12 2018-03-21 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
RU2680267C2 (ru) 2013-03-15 2019-02-19 Мемориал Слоан Кеттеринг Кэнсер Сентер Высокоаффинные антитела к gd2
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
CN110582505B (zh) 2017-04-18 2021-04-02 免疫医疗有限公司 吡咯并苯并二氮杂*缀合物
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
CA3064804A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
KR102270107B1 (ko) 2017-08-18 2021-06-30 메디뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470925A (en) * 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5643756A (en) 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
DE69333115D1 (de) 1992-09-22 2003-08-28 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
ATE267610T1 (de) * 1996-03-20 2004-06-15 Immunomedics Inc Glykosylierte igg antikörper
US5908925A (en) * 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
WO2003025019A1 (en) * 2001-09-20 2003-03-27 Alexion Pharmaceuticals, Inc. Anti-pdgf antibodies and methods for producing engineered antibodies
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules

Also Published As

Publication number Publication date
US20030219861A1 (en) 2003-11-27
PT1461428E (pt) 2012-05-29
EP1461428A2 (en) 2004-09-29
SI1461428T1 (sl) 2012-07-31
ATE550352T1 (de) 2012-04-15
JP4723810B2 (ja) 2011-07-13
EP2298817A1 (en) 2011-03-23
ES2384100T3 (es) 2012-06-29
AU2002359568B2 (en) 2008-02-21
WO2003048321A3 (en) 2003-10-16
AU2002359568A1 (en) 2003-06-17
JP2005511706A (ja) 2005-04-28
JP2012144551A (ja) 2012-08-02
EP1461428B1 (en) 2012-03-21
JP2009153527A (ja) 2009-07-16
WO2003048321A2 (en) 2003-06-12
CA2468744A1 (en) 2003-06-12
JP5054058B2 (ja) 2012-10-24
DK1461428T3 (da) 2012-06-04
CA2468744C (en) 2013-05-14
US7399594B2 (en) 2008-07-15
EP1461428A4 (en) 2005-05-25

Similar Documents

Publication Publication Date Title
CY1112843T1 (el) Μεθοδος παρασκευης υβριδικων αντισωματων
WO2004108889A3 (en) Hybrid antibodies
EP2138512B8 (en) Humanized anti-NGF antibodies
ATE423571T1 (de) Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten
AU2002359851A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
WO2003068801A3 (en) Antibody variants with faster antigen association rates
DE60224346D1 (de) Monoklonales Antikörper gegen das HCV Kernantigen
WO2004029093A3 (en) Humanized anti-granulocyte mn-3 antibody and uses thereof
IN2009KN02655A (https=)
WO2003100008A3 (en) Neutralizing human anti-igfr antibody
ATE530195T1 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
ATE420660T1 (de) Antikörper gegen parath-hormon (pth) und ihre verwendungen
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
WO2004025248A3 (en) Antibody pair screening methods
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
WO2003016501A3 (en) Recombinant antibodies, and compositions and methods for making and using the same
AU2002306748A1 (en) Anti-gpe antibodies, their uses, and analytical methods for gpe
WO2005049652A3 (en) Methods of generating antibody diversity in vitro
WO2023154814A3 (en) Shbg and ibp4 antibodies and methods using same
WO2022140659A3 (en) Anti-cd47 antibodies and uses thereof
김성제 Reflection of Audience's Willing Suspension of Disbelief: An Educational Question of Social Subjectivity in British Cold-War Drama
WO2004019880A3 (en) Aw755252-interacting proteins and use thereof
ATE484523T1 (de) Igg2 antikörper gegen exkretion sekretion antigenen von leishmania promastigoten oder amastigoten
AU2002238858A1 (en) Acetyllysine-recognizing monoclonal antibody and process for producing the same